|
|
|
Volumn 137, Issue 6, 2001, Pages 784-785
|
|
Anti-tumor necrosis factor α therapy in psoriatic arthritis and psoriasis
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CORTICOSTEROID;
ETANERCEPT;
TUMOR NECROSIS FACTOR ALPHA;
ADULT;
AGED;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE DURATION;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
DRUG INDUCED DISEASE;
DRUG SAFETY;
DRUG TOLERABILITY;
FEMALE;
HEADACHE;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
NOTE;
PATHOGENESIS;
PRIORITY JOURNAL;
PSORIASIS;
PSORIATIC ARTHRITIS;
RANDOMIZED CONTROLLED TRIAL;
SKIN INFLAMMATION;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
ARTHRITIS, PSORIATIC;
HUMANS;
IMMUNOGLOBULIN G;
IMMUNOSUPPRESSIVE AGENTS;
PSORIASIS;
RANDOMIZED CONTROLLED TRIALS;
RECEPTORS, TUMOR NECROSIS FACTOR;
RECOMBINANT PROTEINS;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 0034974067
PISSN: 0003987X
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (9)
|
|
References (15)
|
